Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Immunovia Publishes Interim Report for January-March 2024

January-March 2024 · Net sales, which for the quarter only included royalties, amounted to SEK 156 (520) · Net earnings amounted to KSEK -2,946 (-51,658), where exchange rate effects of KSEK 21 358 (435) had a substantial impact. · Earnings per share before and after dilution were SEK -0.07 (-2.28). · Cash Flow from operating activities amount MSEK -24.4 (39.7). · Cash and equivalents at the end of the period amounted to MSEK 51.2 (68.2). · On January 31, the Company announced that Norma Alonzo Palma had been appointed Vice President of Clinical and Medical Affairs

UPM-Kymmene Corporation: Managers’ Transactions (à Porta)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (à Porta)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Martin à Porta as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Maas-Brunner)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Maas-Brunner)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Melanie Maas-Brunner as

UPM-Kymmene Corporation: Managers’ Transactions (Kauppi)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Kauppi)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Piia-Noora Kauppi as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Manner)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Manner)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Topi Manner as follows:   ___

UPM-Kymmene Corporation: Managers’ Transactions (Aaltonen-Forsell)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Aaltonen-Forsell)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Pia Aaltonen-Forsell

UPM-Kymmene Corporation: Managers’ Transactions (Gustafsson)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Gustafsson)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Jari Gustafsson as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Oudeman)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Oudeman)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Marjan Oudeman as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Ehrnrooth)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Ehrnrooth)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 2,816 shares have been purchased to Henrik Ehrnrooth as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Wahl)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Wahl)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,767 shares have been purchased to Kim Wahl as follows:   ________

Press release from Careium AB:s (publ) Annual General Meeting 2024

Careium's Annual General Meeting was held at St Gertrud Konferens, Malmö on Thursday April 25, 2024 at 1 pm. At the Annual General Meeting, the following were resolved, among other things: · to adopt the income statement and the balance sheet, and the consolidated income statement and the consolidated balance sheet for 2023; · to approve the remuneration report; · that no dividend should be distributed in accordance with the proposal from the board of directors; · to grant discharge from liability for the members of the board of directors and the Managing Directors for 2023;

Truqap recommended for EU breast cancer approval

29 April 2024 Truqap plusFaslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50% vs. Faslodex standard of care in a biomarker-altered population AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or

BlueNord: Update on Tyra Redevelopment Project

Oslo, 29 April 2024: Reference is made to stock exchange notice published on 18 April 2024 by BlueNord ASA (“BlueNord” or the “Company”) related to the operational occurrence with the IP compressor temporarily impacting the commissioning of the new Tyra facilities during the ramp-up and testing period. Continued efforts and investigations are ongoing, however, the export volumes from Tyra II are expected to be impacted for the month of May 2024.  Currently, the duration of the testing program and commissioning plan for achieving the technical milestones and driving the ramp-up to 8,1

Invitation to Oneflow’s Q1 2024 presentation on 8 May

Press release29 April 2024 Oneflow will publish its interim report for the first quarter of 2024 on 8 May at 08:00 CET. The report will be presented in a webinar at 10:00 CET the same day. Anders Hamnes, CEO and Founder of Oneflow, and Natalie Jelveh, CFO of Oneflow, will present the report and answer questions. The presentation will be held in English. To join the conference, please register here: https://oneflow.zoom.us/webinar/register/WN_32E2s8s8QPmbbsAJlk4pmg The report and presentation will be available for download on our website here: https://oneflow.com/ir/investors/

Arctic Bioscience – Q1 2024 Operational update – Progress according to plan

Highlights Q1 2024: · The HeROPA clinical trial fully recruited in January 2024, and further development is proceeding as planned   · Available liquidity end of Q1 2024 of NOK 74,6 million · Above 90 % of the total nutra 2023-revenues already secured in 2024 via sales and received purchase orders · Strong growth in the Norwegian Romega market in Q1 2024The HeROPA clinical trial was fully recruited in January 2024. Since then, the clinical trial has progressed according to plan towards 6 months primary end points read-out in second half of 2024. “As the time for read-out is

Quarterly Update – March 2024

29 April 2024 Ashoka WhiteOak Emerging Markets Trust plc (the "Company") Quarterly Update – March 2024 The Company's factsheet as at 31 March 2024 is now available: https://awemtrust.com/factsheet/ The Company has delivered a NAV total return of 11.5% since inception to 31 March 2024, outperforming the benchmark MSCI EM1 (in sterling terms) by 359bps over the same period. Among other factors, stock selection within the small and mid-cap segment has been a key driver of this outperformance. For the first quarter of 2024, the NAV was up 3.9%, outperforming the benchmark by

Skin cancer diagnostic company AI Medical Technology raises SEK12m (US$1m) via an oversubscribed bridge financing round in anticipation of a significant Series A later this year

Stockholm, Sweden, April 29, 2024.  AI Medical Technology today announced the successful closure of an oversubscribed bridge financing round worth SEK12 (US$1m). Funding was provided by existing investors, such as Northern Venture CapSek, and new shareholders.The money will be used to support ongoing regulatory efforts and development of the company’s AI-driven support tool, Dermalyser, a clinically validated decision support tool for the diagnosis of malignant melanomas. Results from a prospective, multicentre, peer-reviewed clinical trial recently published in the British Journal of

Bravida presents investigation regarding overbilling

On April 4, 2024, Bravida initiated an investigation following Region Skåne’s decision to terminate its framework agreements with Bravida Sverige AB. Bravida has reviewed all contracts in the 11 branches that have had Region Skåne as a client.• The investigation reveals that intentional overbilling occurred in the branch that Region Skåne has identified.• In the other 10 branches, no intentional overbilling has occurred. • Bravida will file a police report.• Bravida has also conducted a broader review of other clients with framework agreements in the public sector in Sweden. There are

Africa Oil Announces Results of Share Buyback Program

VANCOUVER, BC, April 29, 2024 /CNW/ - (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, or the “Company”) is pleased to announce that the Company repurchased a total of 1,297,177 Africa Oil common shares during the period of April 22, 2024 to April 26, 2024 under the previously announced share buyback program. The launch of Africa Oil’s normal course issuer bid (share buyback) program, announced by the Company on December 4, 2023, is being implemented in accordance with the Market Abuse Regulation (EU) No 596/2014 (MAR) and Commission Delegated Regulation (EU) No 2016/

Enhertu improved PFS in HER2-low and ultralow

29 April 2024 Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial AstraZeneca and Daiichi Sankyo's Enhertu also demonstrated a clinically meaningful progression-free survival improvementin patients with HER2-ultralow expression Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and

CapMan Infra’s second fund reaches final close at €375 million, twice as large as its predecessor

CapMan Infra press release29 April 2024 at 09:00 a.m. EEST CapMan Infra’s second fund reaches final close at €375 million, twice as large as its predecessor The CapMan Nordic Infrastructure II fund made its final closing at more than €375 million. Established in 2022, the fund has already made four investments and will continue investing in energy, transportation, and digital infrastructure across the Nordics in line with its strategy. Since 2017, CapMan Infra has raised a total of approximately €800 million in capital, which is managed by a team of 13 professionals based in

Raksystems announces rebranding as Sustera Group

With the new strategy launched, the group aims to triple its revenue and significantly grow the number of personnel, and expand to several new countries in the coming years. To support the growth strategy, the company announces its rebranding as Sustera Group.· Sustera specialises in supporting clients throughout the lifecycle of their properties. The company aims to accelerate the change towards more sustainable construction and more responsible building management, driven strongly by EU regulations. · Through the new strategy launched for 2024–2028, Sustera aims to increase its revenue

YIT deepens collaboration with Czech partner RSJ Investments and establishes three joint ventures to develop large area projects

YIT Corporation Investor News 29 April 2024 at 9:00 a.m.YIT deepens collaboration with Czech partner RSJ Investments and establishes three joint ventures to develop large area projects YIT has signed agreements to establish three joint ventures with the Czech investment group RSJ Investments in Lithuania, Latvia, and Slovakia. YIT will sell plots or projects under construction to the joint ventures under the same agreement. The deals cover the fifth stage of the Naujasis Skansenas project in Lithuania, the second stage of the Mārpagalmi project in Latvia, and the Mlynarka project in

There are no items matching the current filter
There are no more items matching the current filter
Back to top